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Pesticide Use in Developing
Countries
A World Health Organization/United
Nations working group estimated in a 1990
report, Public Health Impact ofPesticides
Used in Agriculture, that 3 million people
worldwide suffer acute pesticide poisonings
each year, and that a disproportionate bur-
den of such poisonings is shouldered by
people ofthedevelopingworld. The condu-
sions ofthis working group's report sparked
a collaborative agreement between the
Pesticide Program ofUniversidad Nacional
of Costa Rica (PPUNA) and the Swedish
International Development Agency (SIDA),
which culminated in the International
Conference on Pesticide Use in Developing
Countries: Impact on Health and Envir-
onment. The conference, which was held in
SanJosd, Costa Rica, 23 February-1 March
1998, investigated the causes ofthis dispari-
ty and what can be done to change it.
Conference participants also toured nearby
organicand cooperative farms.
PPUNA and SIDA have supported sev-
eral studies on pesticides in the developing
world, particularly in Costa Rica. One
study, coauthored by Catharina Wesseling
and Luisa Castillo of PPUNA and pub-
lished in the August 1993 issue of the
ScandinavianJournalofWork, Environment
and Health, estimated the usage of pesti-
cides in Costa Rica during the last decade
to be 4 kg per capita annually in the last
decade, eight times the estimate for the
world population. Today, there are indica-
tions thatthe useofpesticides in CostaRica
is declining through the change from an
agricultural exports-based economy to one
based on ecotourism and increased organic
farming.
Over half the pesticides used in Costa
Rica are used on plantations that raise
bananas, a major agricultural export. One
effort towards reduction ofpesticide use is
Ecos del Agro, an organic banana farm
located in Guapiles. The farm is currendy
the onlycommercial enterprise in the world
producing a particular variety ofpest-resis-
tant banana developed by the Honduran
Foundation for Agricultural Research.
Exportation of organic bananas to North
America will begin this year. Refuse from
surplus bananas-bark and leaves, for
instance-is used to make paper products.
In fact, materials for the International
Conference on Pesticide Use in Developing
People at risk. Toxic exposures from unprotect-
ed application of pesticides is a major health
concern inthe developing world.
Countries were printed on paper made
through thisprocess.
Another example ofsustainable agricul-
tural practices in Costa Rica is Jugar del
Valle, an organic agriculture training center
near the town ofZarcero. The center was
founded bylocal farmers to reduce pesticide-
related disease in theircommunity bysharing
knowledge ofalternatives to chemical pesti-
cides. They started by gathering the knowl-
edge of community elders about farming
practices used prior to the widespread avail-
ability ofpestiddes. After years ofproducing
only subsistence products, this cooperative
farm is now asupplier for Costa Rica's main
supermarket dcain. To date, over 350 people
have completed the training program, 20%
ofthem from other countries. The center-
pieceoftheprogramis innovativeapproaches
to producing fermented fertilizers. Felicia
Echevarria, director ofthe training center,
explains, "[Our] motivation is to leave in the
earthwhatis initthatisgood, so thatitgives
usthingsthatareevenbetter."
The conference highLighted these success-
es and pointed out areas in need ofmore
research. David Pimentel, aprofessorofento-
mology at Cornell University's College of
Agriculture and Life Sciences in Itaca, New
York, estimated the economic impact ofpes-
ticides on nontarget species (including
humans) atapproximately$8billionannually
in developing countries. Although only 20%
ofpesticides produced worldwide are used in
developing countries, these countries experi-
ence more than halfthe pesticide poisonings,
Pimentelsaid.
Rob McConnell, former director of the
Pan American Health Organization and now
an associate professor ofenvironmental and
occupational medicine at the University of
Southern California in Los Angeles, stated
that outbreaks ofpesticide poisonings can be
used to support changes in policyaround the
world. To achieve this goal, he proposed that
universities establish surveillance mechanisms
to monitor poisoning outbreaks and provide
scientific literature and epidemiological
results to government agencies. McConnell
gave examples ofoutbreakepidemiology used
as a tool to develop protective pesticide poli-
cies in Latin America, such as the case ofan
epidemic ofcarbofuran and methamidophos
poisoning in Nicaragua in the mid-1980s
that led the country's Ministry ofLabor to
listpesticide poisoningamongthe fivepriori-
typreventable diseases for thesubsequent tri-
ennialplan.
However, Carina Salazar, coordinator of
research projects for La EraAgricola, an edu-
cational program for Venezuelan farmers
located in Merida, pointed out that the
results of many studies of outbreaks of
human pesticide poisonings had not been
shared directly with affected communities.
She arguedthatidentifying adirectbenefit to
affected communities must be an integral
partofsuchresearch.
Community outreach, effective environ-
mental health monitoring, preventive strate-
gies, implementation ofpractices that reduce
pesticide usage, and health promotion mea-
sures were identified as areas that need more
extensive international attention. A complete
conference report is slated for publication in
the May 1998 issue ofAMBIO, the journal
ofthe Royal Swedish Academy of Sciences
(dueoutinmid-August).
The Relentless Flu Drug
Justas itis always momingsomewhere in the
world, soalsoisitalwaysfluseason. Buthope
may be dawning for the thousands ofpeople
worldwide who suffer the misery ofthe flu
each year. The Australian influenza drug
GG167, also known as Relenza orzanamivir,
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began regulatory and commercial testing in
earlyApril, with sales to the public anticipat-
edfor the 1998-1999 flu season. Relenza, the
result of three decades' worth of research, is
what Tom Spurling, chief of the division of
molecular science at the Commonwealth
Scientific and Industrial Research
Organisation (CSIRO), headquartered in
Melbourne, Australia, calls "the world's first
antiviral drug for the treatment ofall strains
offlu."
The development ofthe new drug is the
result of a collaboration between Graeme
Laver, a visiting fellow at the John Curtin
School of Medical Research at Canberra's
Australian National University, CSIRO sci-
entist Peter Colman (now head of the
Biomolecular Research Institute [BRI] in
Melbourne), and a team ofinvestigators led
by Mark von Itzstein, head ofthe medicinal
chemistry department at Monash
University's Victorian College of Pharmacy
in Parkville, Australia. The scientists,
backed by the pharmaceutical companies
Biota Holdings and Glaxo Wellcome
Australia, have created a treatment that
appears to offer effective relief against the
annual scourge.
Relenza works by blocking the catalytic
activity ofthe enzyme neuraminidase-also
known as sialidase-on the influenza virus.
Neuraminidase helps in the spread ofinfec-
tion by releasing the flu virus from an
infected cell and allowing it to pass to adja-
cent healthy cells.
Laver's early work with the enzyme
includes a paper published in the May 1969
issue of Virology that first described the
morphology of the neuraminidase subunit
within the influenza virus. This led to using
the process of X-ray crystallography to
delineate the crystal structure of the
enzyme. Explains Colman, "X-ray crystal-
lography gives a hundred million-fold mag-
nification ofthe virus. It is a complex pro-
cedure, requiring sophisticated instrumen-
tation and computational facilities. And to
determine the crystal structure ofa protein,
first you need to isolate it, purify it, and
then crystallize it. None of these are trivial
tasks." In 1978, Laver successfully grew
neuraminidase crystals of a high enough
quality to begin the X-ray crystallography
process, and joined forces with Colman and
colleagues to map out the structure of the
enzyme. By 1987, Colman and colleagues
had fully identified the crystal structure of
neuraminidase.
At this point, Colman and colleague
Jose Varghese noticed a feature that they
came to realize is common to all flu strains:
a small "pocket" on the surface of the pro-
tein that is actually the active site of neu-
raminidase. The scientists realized that the
strain-invariant neuraminidase receptor site
might serve as a weak link that could be
exploited in order to treat influenza.
Working from Colman's lead, von Itzstein's
team was able to design and subsequently
synthesize the neuraminidase inhibitor that
is used in Relenza. Relenza works by plug-
ging the receptor pocket, thereby blocking
the catalytic activity of neuraminidase,
which prevents the flu from reproducing
and spreading.
At first, many researchers were doubtful
that the inhibitor would work, believing
that the incredibly fast rate at which flu
viruses can mutate and adapt to new hosts
meant it would be impossible to target all
strains of flu with one drug. But these
doubts have been allayed by the perfor-
mance of Relenza and other experimental
neuraminidase inhibitors being developed
around the world, such as GS4104, an oral-
ly administered drug developed jointly by
Gilead Sciences of Foster City, California,
and Hoffmann-La Roche of Nutley, New
Jersey, that has been shown to be effective
against influenza strains A and B in in vitro
clinical trials.
Relenza is delivered to the primary site
of infection, the lungs, as either a nasal
spray or asniffable powder. The medication
appears to work best when administered
within 30-36 hours of infection. When
taken soon after infection with influenza,
test subjects demonstrated a much shorter
duration of infection and blunted symp-
toms. Even high-risk patients in the studies,
such as the elderly and the immune-com-
promised, benefited from using Relenza.
Because the drug acts by stopping the
spread of the flu virus, it is less effective if
administered after flu symptoms begin to
appear. To counter this potential dilemma,
laboratories around the world are working
to develop simple, rapid diagnostic tests for
influenza that people can use at the doctor's
office or at home to determinewhether they
have been infected with the flu. Laver esti-
mates that some type ofhome rapid-detec-
tion kit may be available by the time
Relenza hits pharmacy shelves.
Given the flu's capacity for rapid shift-
ing, the question arises whether flu viruses
might mutate in such a way that the neu-
raminidase inhibitor would no longer be
effective. von Itzstein doesn't think so. "It is
possible that the virus can mutate upon
exposure to high doses of the drug [and]
work has been published on this already in
nonclinical studies," he says. "However, the
clinical relevance of this result is yet to be
determined. It is clear that if the virus sig-
nificantly alters its active site pocket, it may
well reduce its own infectivity." Colman
adds, "[Selection for mutation is] always a
possibility with any antiviral drug. Our
drug looks promising in the sense that resis-
tance is less likely than usual."
EPASPM2.5 Program Criticized
In May, the National Research Council
(NRC), the research arm of the National
Academy ofSciences, entered the debate over
the EPA's new air qualitystandard for partic-
ulate matter smaller than 2.5 microns in
diameter (PM2.5) by issuing a report that
strongly criticizes how the EPA has allocated
funds to study these air pollutants. The
report, which was requested by Congress,
states that the EPA is directing too many of
its resources toward monitoring concentra-
tions of the fine particles in air and toward
determining the sources ofthe pollution. On
the other hand, the report says, the EPA is
notdoing enough to investigatehuman expo-
sures, and its efforts to determinewhich types
of particulate matter are likely to harm
human health are"cruciallyinadequate."
The new National Ambient Air Quality
Standard for PM2.5 was set by the EPA in
July 1997, despite heavy opposition from
many industry groups. The goal of the law,
which supplements the EPA's standard for
particles less than 10 microns in diameter
(issued in 1987), is to protect thepublic from
the very small particles that can be inhaled
most deeply into the lungs. Several epidemio-
logical studies have found an association
between exposure to PM25 andserious health
problems including exacerbation ofasthma,
decreased lung function, respiratory diseases,
andprematuredeath.
The debate over the newPM2.5 standard,
however, centers on the fact that particulate
matter, the visible component ofsmoke and
haze, indudes awidevarietyofbothsolidand
liquid partides from diverse sources induding
forest fires, wind erosion, road construction,
and fossil fuel combustion. Little is known
about exactly which of these particles cause
health problems orbywhat biological mecha-
nisms they act. Business groups argued to the
EPA and Congress that the new PM2 stan-
dardwas unfairbecause industrieswou?d like-
ly bear the economic brunt ofthe regulation
despite a lack of evidence linking specific
sources or industries to the particles that
affecthealth.
Congress responded to the argument by
putting extra money in the EPA's 1998 bud-
get for filling the gaps in the science support-
ing the PM25 standard. Part of this money
was earmarked to fund a study ofthe EPA's
PM25 research and monitoring program, to
be completed by the NRC. Congress man-
dated that the NRC produce four reports on
PM25 research needs, of which the May
report, Research Priorities for Airborne
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